Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Public ClinicalTrials.gov record NCT00046683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Study identification
- NCT ID
- NCT00046683
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 284 participants
Conditions and interventions
Conditions
Interventions
- alemtuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2001
- Primary completion
- Not listed
- Completion
- May 31, 2006
- Last update posted
- Jul 27, 2016
2001 – 2006
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Hines | Illinois | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Paducah | Kentucky | — | — |
| Not listed | Lafayette | Louisiana | — | — |
| Not listed | Jackson | Mississippi | — | — |
| Not listed | Tupelo | Mississippi | — | — |
| Not listed | Jefferson City | Missouri | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Billings | Montana | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | New Hyde Park | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Sioux Falls | South Dakota | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00046683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2016 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00046683 live on ClinicalTrials.gov.